Kornimate/medical-research-clean huggingface dataset:
stellate ganglion block

Conditions: Esophagectomy; Pneumonectomy; Lobectomy

Summary: the purpose of this study is to determine if the addition of an ultrasound guided left sided stellate ganglion block with bupivacaine in patients undergoing esophagectomy, pneumonectomy, or lobectomy will result in lower rates of postoperative atrial fibrillation as compared to standard of care.


Eligibility criteria:
inclusion criteria: * patients undergoing esophagectomy, pneumonectomy, or lobectomy aged 18-85. exclusion criteria: * patients who have an exclusion to regional anesthesia. * patients who have exclusion to stellate blockade. * patients who are pregnant assessed via self-report or pregnancy test if they have taken one

Keywords: esophagectomy pneumonectomy lobectomy stellate ganglion block
neoadjuvant camrelizumab combined with chemotherapy for resectable stage iiia-iiib nsclc

Conditions: IMMUNOTHERAPY; Neoadjuvant Therapy; Resectable Lung Non-Small Cell Carcinoma; Biomarkers / Blood

Summary: this study aims to evaluate the efficacy and safety of neoadjuvant camrelizumab combined with chemotherapy in resectable stage iiia and iiib (t3-4n2) non-small cell lung cancer (nsclc) patients. inclusion criteria are: age 18-75, pathologically confirmed resectable stage iiia-iiib (t3-4n2) nsclc, absence of egfr, alk, and ros1 gene mutations, and eastern cooperative oncology group (ecog) status 0-1. all patients receive three cycles of camrelizumab combined with platinum-based doublet chemotherapy, followed by curative surgery within 4-6 weeks after completion of chemotherapy. patients undergo 18f-fluorodeoxyglucose (fdg) pet/ct scans in 1 week before treatment and 1 week before surgery, and peripheral blood samples are collected for biomarker analysis. the primary endpoints for follow-up are pathologic complete response (pcr) rate and major pathological response (mpr) rate, while secondary endpoints include safety and progression-free survival. exploratory endpoints include molecular imaging research and biomarker analysis.


Eligibility criteria:
inclusion criteria: * age 18-75 * pathologically confirmed resectable stage iiia-iiib (t3-4n2) nsclc * absence of egfr, alk, and ros1 gene mutations * eastern cooperative oncology group (ecog) status 0-1 * signed written informed consent prior to the implementation of any trial-related rocedures * adequate organ function, evidenced by laboratory results with no contraindications to chemotherapy: absolute neutrophil count ≥ 1,500 х109/l, thrombocytes ≥ 100 х 109/l, hemoglobin ≥ 90 mg/l, creatinine ≤ 1.5 x uln or creatinine clearance (calculated using the cockcroft-gault formula) ≥ 40 ml/min, alanine aminotransferase (alt) and aspartate aminotransferase (ast) \&gt; 2.5 x upper limit of normal (uln), alkaline phosphatase (alp) \&gt; 5 x uln, bilirubin \&gt; 1.5 х uln exclusion criteria: * patients diagnosed with any other malignant tumor * have received prior therapy with chemotherapy or immune checkpoint inhibitor * insufficient caloric and/or fluid intake despite consultation with a dietitian and/or tube feeding * have an active infection requiring systemic therapy that has not resolved 3 days (simple infection, such as cystitis) to 7 days (severe infection, such as pyelonephritis) before the first dose of trial treatment * patients who cannot tolerate chemoradiotherapy or surgery due to severe cardiac, lung dysfunction * a history of interstitial lung disease or non-infectious pneumonia * active autoimmune disease with systemic therapy (ie, use of disease modifiers, corticosteroids, or immunosuppressive drugs) in the past 2 years * known history of human immunodeficiency virus (hiv) infection (i.e., positive for hiv 1/2 antibody) and various viral hepatitis infections * patients who have received allogeneic stem cell or solid organ transplantation * women during pregnancy or lactation

Keywords: camrelizumab non-small cell lung cancer neoadjuvant therapy biomarkers analysis
testing an online insomnia intervention

Conditions: Alcohol Use Disorder; Insomnia

Summary: the objective of this trial is to determine the effectiveness of an electronic cognitive behavioral therapy for insomnia (e-cbt-i) module in improving sleep and reducing alcohol use among heavy drinkers with insomnia. specifically, it will test the effectiveness of sleep healthy using the internet (shuti), a well-validated version of e-cbt-i comprised of 6 weekly educational modules and daily sleep diaries. the rationale for this mixed methods proposal is that effective, nonpharmacologic treatments are necessary to stem the highly comorbid public health problems of alcohol use disorder (aud) and insomnia. if successful, shuti will represent a novel and easily accessible intervention for reducing alcohol intake among high-risk heavy drinkers.


Eligibility criteria:
inclusion criteria: * engage in weekly alcohol binge episodes * moderate to severe insomnia exclusion criteria: * history of severe alcohol or other substance use disorder * obstructive sleep apnea * schizophrenia * bipolar disorder * psychotic spectrum disorder * lack of internet access * lack of english fluency * pregnant or nursing

Keywords: sleep cognitive behavioral therapy cbt electronic alcohol non-pharmacological
uro-nirs clinical study

Conditions: Lower Urinary Tract Symptoms; Overactive Bladder

Summary: the purpose of this experiment is to confirm the results of previous testing of urodynamix's uro-nirs device. together urodynamix and laborie have created a device that includes standard laborie medical equipment and the experimental urodynamix device. collectively this integrated device is considered an investigational device, and the results from this study may be used to support a submission to the us food and drug administration for the approval of the integrated device. this research is being done because we want to test the ability of the integrated laborie and urodynamix device to provide a non-invasive method to provide additional information to assist with the diagnosis of or treatment plan of patients suffering from urinary problems. the current technologies rely solely on the measurement of internal pressures of the bladder, which involves the insertion of catheter into the subject's urethra.

this is a study of the fully integrated uro-nirs:uds device (laborie triton or laborie dorado and urodynamix's non-invasive urodynamics device - uro-nirs), to confirm the results using the fully integrated uro-nirs:uds device as compared to the stand-alone uro-nirs device and uds device. the study will evaluate male patients with lower urinary tract symptoms (luts) and female subjects with over-active bladder (oab). the uro-nirs unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome from the detrusor muscle from the human bladder wall. this process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). previous clinical feasibility studies have identified the correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures and uroflow procedures. for this study the uro-nirs results specifically will not be used by the urologist/nurse to guide in patient management and treatment decisions, but rather will only be used to collect measurements from the patient. the uro-nirs sensor patch will be adhered to skin surface where their bladder is located. the study will be conducted by the two principal investigators at the two clinical study sites who will collectively enrol a minimum of 50 subjects, with a minimum of 35 male subjects and a maximum of 15 female subjects. the study enrolment objective is to equally enrol male subjects into three categories: unequivocal, obstructed and unobstructed. female subjects shall all have oab.

Eligibility criteria:
inclusion criteria: * subjects must be 18 years of age or older. * subjects are patients of one of the institutions and are currently scheduled for uds * male subjects must have luts * female subjects must have oab * subjects must give their informed consent prior to enrollment. exclusion criteria: * the patient has an existing health condition which the investigators feel will not allow for safe or accurate measurements with the uro-nirs:uds device.
feasibility of 123i-ibzm scintigraphy (a d2 agonist) in patients with pheochromocytoma (pheo) and/or paraganglioma (pgl) : study pilot

Conditions: Chromaffin-tissue Derived Tumors

Summary: context. nuclear imaging plays a central role in management of chromaffin-tissue derived tumors because tumor cells exhibit peptide receptors and proteins involved in metabolism that can be targeted with specific radiopharmaceutics. recently, over expression dopamine-receptor d2 isoforms has been found in endocrine tumors. objective. the aim of the present study is to evaluate the feasibility of 123i-ibzm (a d2 agonist radiolabelled with 123i) in patients with pheo and/or pgl. diagnostic accuracy will be also compared to traditional spect imaging procedures.


Eligibility criteria:
inclusion criteria: * age + 18 years. the women in ages to procreate have to have an effective contraception or a negative pregnancy test (in the absence of effective contraception) having a radiological and functional imaging (balance sheet(assessment) pré--ibzm) considered adapted and complete for the pathology. * having a phéochromocytome or a paragangliome proving a surgical operation in view of the data of the balance sheet(assessment) pré--ibzm. * with or without allergy in the iodine. exclusion criteria: * nem2a or 2b. * malignant forms which do not recover from an even partial, surgical gesture(movement). * pregnant women or in the course of feeding. * women in age to procreate without effective contraception, with positive pregnancy test. * renal insufficiency
sound and music for mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: emerging studies in humans found that 40 hz sound induces neural gamma oscillation and enhanced cognitive function in older adults with and without alzheimer's disease. we will compare a 40 hz music intervention to both 40 hz sound and music alone in a clinical cohort of older adults with mild cognitive impairment.


Eligibility criteria:
inclusion criteria: 1. community-dwelling 2. amnesia mild cognitive impairment 3. preserved function 4. no dementia exclusion criteria: 1. known diagnosis of schizophrenia or parkinson's disease; 2. severe hearing impairment; 3. presence of an acute medical or psychiatric condition which would interfere with the subject's ability to follow the study protocol realistically
experimental expanded access treatment with convalescent plasma for the treatment of patients with covid-19

Conditions: COVID; Sars-CoV2; Corona Virus Infection

Summary: the purpose of this program is to see if giving convalescent plasma to individuals who test positive for covid-19 may reduce their symptoms and help minimize complications from the illness.

as individuals are exposed to pathogens, the body's immune system works to create antibodies toward those pathogens. these antibodies can be found in the plasma portion of the blood. this plasma is referred to as "convalescent plasma" and contains these infection fighting antibodies. through a blood donation, this convalescent plasma is collected from a recovered person and transfused to a sick patient who is still fighting the same virus. this protocol will make convalescent covid-19 plasma available to individuals who meet the eligibility criteria described.

Eligibility criteria:
inclusion criteria: * at least 12 years of age * covid-19 convalescent plasma (ccp) treatment is in line with the patient's current goals of care (i.e. recipient cannot be dni status) * laboratory confirmed diagnosis of infection with sars-cov-2 that is severe or life threatening or the individual is judged by the treating provider to be at a high risk of progression to severe or life-threatening disease. * severe covid-19 is defined by one or more of the following: 1. dyspnea 2. respiratory frequency ≥ 30/min 3. blood oxygen saturation ≤ 93% 4. partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300 5. lung infiltrates \> 50% within 24-48 hours * life-threatening covid-19 is defined as one or more of the following: 1. respiratory failure 2. septic shock 3. multiple organ dysfunction or failure exclusion criteria: * history of prior life-threatening reactions to transfusion of blood products * not receiving other therapies that would preclude plasma transfusion

Keywords: covid-19 coronavirus sars-cov2
the evaluation of nets, caspase-1 and cytokines in ards patients

Conditions: ARDS

Summary: 1. enrollment criteria and clinical data collection: follow the principles of medical ethics, the development of inclusion and exclusion criteria, select 90 cases of ards patients, in the active treatment at the same time, according to the berlin standard severity of the disease divided into mild group, moderate group and severe group, according to the prognosis during hospitalization is divided into survival group and death group. balf specimens were collected on the day of admission to detect the levels of nets and alveolar macrophages. the acute and chronic health status scoring system ⅱ (apacheⅱ) and murray acute lung injury score, blood routine, creatinine, urea nitrogen, fasting blood glucose, item, mean arterial pressure, arterial blood gas analysis, oxygenation index; record the patient's mechanical ventilation time and other data; 2. pearson linear correlation analysis of balf in the content of nets, alveolar macrophage coke death level was a positive correlation between the spearman rank correlation analysis balf in the nets content and alveolar macrophage coke death level, apache ⅱ, murray score, creatinine, urea nitrogen, fasting blood glucose and other indicators and ards severity was positively correlated; 3. to analyze the prognostic factors of different prognostic factors, to evaluate the content of nets in balf, the level of alveolar macrophage coke, apacheⅱ and murray scores were analyzed by receiver operator characteristic curve (roc curve) short - term survival outcome prognostic value.


Eligibility criteria:
inclusion criteria: * ards patients diagnosis within 3 days * over 18 years old but no more than 75 years old exclusion criteria: * severe thoracic open trauma * pulmonary embolism * severe cardiovascular and cerebrovascular disease * endocrine system diseases * coagulation dysfunction * liver and kidney failure * malignant tumors * cardiogenic pulmonary edema
bi 409306 in patients with cognitive impairment due to alzheimer's disease.

Conditions: Alzheimer Disease

Summary: the study is designed to compare the effects of bi 409306 compared to placebo in patients with cognitive impairment due to alzheimer's disease


Eligibility criteria:
inclusion criteria: * patients with early signs of dementia of alzheimer type * male and female patients with an age of at least 55 years * previous use of alzheimer's disease (ad) medications (acheis, memantine) is allowed up 3 month prior to screening. patients who are currently taking acheis are eligible as long as they have been using a stable dose for at least 3 months prior to screening and no change is foreseen for the duration of the study. this dose must be consistent with the product label in the concerned country. patients currently taking memantine are excluded. * patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator. * patients must have a reliable study partner (per investigator judgement, for instance a family member, partner etc., guardian or, if applicable, a legal representative) exclusion criteria: * cognitive impairment or dementia with any etiology other than alzheimer's disease (ad) * substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement * medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement * any other psychiatric disorders such as schizophrenia, or mental retardation * previous participation in investigational drug studies of mild cognitive impairment/dementia of alzheimer type (dat) within three months prior to screening. having received active treatment in any other study targeting disease modification of ad like aß immunization and tau therapies. previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed. * clinically significant uncompensated hearing loss in the judgment of the investigator. use of hearing aids is allowed.
post-marketing drug intensive monitoring surveillance of edirol in patients with postmenopausal osteoporosis

Conditions: Postmenopausal Osteoporosis

Summary: this is a post-marketing drug intensive monitoring surveillance with an observational, non-interventional design. the objectives are to compare the incidence of hypercalcemia in patients with and without calcium intake (including dietary supplements, excepting calcium from meals), and to monitor the type, incidence, severity, and relevance of other adverse drug reactions,including urolithiasis.


Eligibility criteria:
inclusion criteria: * postmenopausal osteoporosis patients who signed the informed consent form and are expected to receive edirol during the intensive monitoring period. * patients with postmenopausal osteoporosis * patients who signed the informed consent form * patients who are expected to receive edirol during planned enrollment period exclusion criteria: * exclude if any of the following: * men * no osteoporosis * other osteoporosis (not postmenopausal) * started edirol before icf signature * did not sign icf
effect of intensive nutritional support in subacute stroke patient

Conditions: Stroke; Rehabilitation; Nutrition

Summary: proper nutritional support during early rehabilitation may be beneficial for functional improvements in gaining functional independence and preventing complications in stroke patients. however, there was no consensus of proper amount of nutritional support in stroke patients. in this study, the investigators aimed to clarigy the effects of the intensive nutritional support during comprehensive rehabilitation during subacute phase to improve function in patients with first-ever strokes.


Eligibility criteria:
inclusion criteria: * acute first-ever stroke patients less than 7 days after onset * more than 19 years old at stroke onset ③ stroke confirmed by brain ct or mri * body mass index (bmi) \<25 before the comprehensive rehabilitation ⑤ mini nutritional assessment \< 12 before the comprehensive rehabilitation ⑥ fugl-meyer assessment \< 85 at 7 days after stroke onset exclusion criteria: * transient ischemic stroke * progressive or unstable stroke * pre-existing and active major neurological disease, e.g., spinal cord injury, parkinson's disease, et al. * pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease or dementia ⑤ advanced liver, kidney, cardiac, or pulmonary disease, e.g., advanced hepatocellular carcinoma, end-stage renal failure, et al.) * a terminal medical diagnosis consistent with survival \< 1 year * diabetes mellitus, hyperlipidemia, metabolic syndrome, heart failure) ⑧ pregnant or lactating women ⑨ prohibited from taking medication (omapone peri 724ml or winuf peri 654ml)
stereoeeg motor neuronal potentials decoding

Conditions: Drug Resistant Epilepsy; Brain-Computer Interfaces

Summary: the goals of this study are (1) to evaluate the rate of stereoeeg brain-computer interface (bci) classification accuracy and (2) to collect the dataset of neuronal signals recorded from stereoeeg electrodes during motor performance, motor imagery or brain-computer interface control. the study enrolls hospitalised patients suffering from resistant epilepsy with already implanted intracranial stereoeeg electrodes for medical reasons (i.e. for preoperative localization of the epileptogenic foci). the number and location of electrodes are determined solely for the clinical purposes of stereoeeg monitoring and are not related to the protocol of the current study. after obtaining informed consent to participate in the study, each patient will participate in one experimental session lasting no more than 60 minutes, recording brain signals associated with hand movement, motor imagery, and bci control. all tasks and instructions presented during the study session are not pro-epileptogenic and cannot provoke an epileptic attack. the experiments will take place in the patient's room, without interruption of observation by the department's medical staff. the data recorded in this study will be used to improve or develop new algorithms for decoding motor signals from deep brain structures for their potential use in invasive bcis.


Eligibility criteria:
inclusion criteria: * male and female patients who have had stereoeeg electrodes implanted for medical reasons; * voluntary informed consent to participate in the study; * age from 18 to 70 years. exclusion criteria: * patient refusal to participate in the study; * cognitive impairment that prevents following the study instructions; * severe visual impairment that does not allow viewing visual instructions on a computer screen; * upper limb paresis or other motor disorders; * pain in the hand of any etiology; * any acute diseases, exacerbation of chronic diseases, acute life-threatening conditions; * occurrence of an epileptic attack during the experiment.

Keywords: brain-computer interface motor imagery motor performance intracranial electroencephalography
acute mesenteric venous thrombosis.. in assiut university hospital management controversies

Conditions: Mesenteric Vein Thrombosis

Summary: initial treatment in the management of acute mesenteric vein thrombosis (mvt) is controversial. some authors have proposed a surgical approach, whereas others have advocated medical therapy (anticoagulation). in this study, the investigators analyzed and compared the results obtained with surgical and medical treatment to determine the best initial management for this disease.

mesenteric venous thrombosis (mvt) is increasingly recognized as a cause of mesenteric ischemia. it must be distinguished from arterial and non occlusive types of ischemia, it accounts for 5% to 15% of all cases of mesenteric ischemia. patients may have evocative signs,such as abdominal pain that is out of proportion to physical signs, nausea, or vomiting. however, a clinical diagnosis is often difficult because abdominal symptoms are non specific and high index of suspicion is often required for diagnosis.(1) primary mvt accounted for 25% to 55% of cases in early studies, but recent reports show decline in primary mvt because of improvements in the diagnosis of hypercoagulable states.(2) advances in new imaging techniques also have enabled early recognition of this disease without or before laparotomy.(3-5 ) fortunately , there is no consensus about the initial management of mvt; some authors have proposed an aggressive surgical approach (6) while others have advocated an initial conservative management with anticoagulation and close monitoring . ( 7) similarly,issue of second look laparotomy,mandatory or selective is yet not resolved. the present study is prompted to analyze our experience in an effort to resolve these controversies and the results obtained will be assessed to determine the best management strategy for this uncommon disease.

Eligibility criteria:
inclusion criteria: * 1. patients admitted in the department of surgery in assiut university diagnosed to have mesenteric venous occlusion not presented by signs of peritonitis or confirmed radiological signs of bowel infarction. exclusion criteria: 1-patients diagnosed to have mesenteric venous occlusion but with signs of peritonitis or confirmed radiological signs of bowel infarction on admission.